Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
View ORCID ProfileLuis Rosero-Bixby
doi: https://doi.org/10.1101/2021.11.08.21266087
Luis Rosero-Bixby
Universidad de Costa Rica, Centro Centroamericano de Población (CCP)
Roles: Emeritus Professor

Article usage
Posted November 09, 2021.
Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
Luis Rosero-Bixby
medRxiv 2021.11.08.21266087; doi: https://doi.org/10.1101/2021.11.08.21266087
Subject Area
Subject Areas
- Addiction Medicine (217)
- Allergy and Immunology (496)
- Anesthesia (106)
- Cardiovascular Medicine (1112)
- Dermatology (141)
- Emergency Medicine (275)
- Epidemiology (9807)
- Gastroenterology (482)
- Genetic and Genomic Medicine (2335)
- Geriatric Medicine (223)
- Health Economics (464)
- Health Informatics (1569)
- Health Policy (738)
- Hematology (238)
- HIV/AIDS (508)
- Medical Education (240)
- Medical Ethics (67)
- Nephrology (258)
- Neurology (2162)
- Nursing (134)
- Nutrition (340)
- Oncology (1187)
- Ophthalmology (366)
- Orthopedics (129)
- Otolaryngology (221)
- Pain Medicine (148)
- Palliative Medicine (50)
- Pathology (314)
- Pediatrics (700)
- Primary Care Research (268)
- Public and Global Health (4694)
- Radiology and Imaging (786)
- Respiratory Medicine (625)
- Rheumatology (276)
- Sports Medicine (214)
- Surgery (252)
- Toxicology (43)
- Transplantation (120)
- Urology (94)